News

News

bit.bio launches Early Access programme for ioHepatocytes, a new iPSC-derived liver model

bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepatocytes for long-term liver research in 2D culture.

05.11.2025

Published by bit.bio

bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepatocytes for long-term liver research in 2D culture.

Published by bit.bio

Read now

Press Release

bit.bio Raises $30 Million Led by M&G Investments

Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.

11.08.2025

Published by bit.bio

Read now

Press Release

bit.bio launches first-of-their-kind human iPSC-derived cells for gene activation and interference, expanding functional genomics product range

Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...

03.03.2025

Published by bit.bio

Read now

Press Release

bit.bio Launches ioTracker Cells Range at SLAS 2025

Adding New Visualisation Functionality to Human iPSC-derived Cell Types

03.02.2025

Published by bit.bio

Read now

Press Release

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the bro...

16.10.2024

Published by bit.bio

Read now

Press Release

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference.

01.10.2024

Published by bit.bio

Read now

Press Release

bit.bio Honoured as Life Science Innovation at the 2024 Business Weekly Awards

bit.bio Wins Honours for Innovation in Synthetic Biology and Exceptional Business Growth.

12.09.2024

Published by bit.bio

Read now

board leadership

bit.bio expands Executive Team with appointment of Przemek Obloj as Chief Financial Officer

bit.bio appoints new Chief Financial Officer, Przemek Obloj

31.07.2024

Published by bit.bio

Read now

Press Release

bit.bio launches 16 disease models for neurodegenerative disease

bit.bio launches panel of 16 neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s disea...

24.07.2024

Published by bit.bio

Read now

Related pages

Join our pioneering team